New Delhi, November 2014 –
Synergy Pharmaceuticals Inc said its experimental drug for opioid-induced constipation was found safe and effective in a mid-stage trial.
Synergy Pharmaceuticals shares were up 8 percent in premarket trading
The drug SP-333 showed statistically significant improvement in spontaneous bowel movement in the fourth week of treatment, compared with a placebo, the company said on Wednesday.
The study was designed to evaluate the effect of a once-daily oral tablet against placebo in patients who had less than three spontaneous bowel movements per week and experienced constipation-related symptoms.
Synergy said the experimental drug was found safe and well tolerated at all doses and it expects to evaluate the full dataset in the coming weeks.
The company is also developing another constipation drug called Plecanatide which is currently in a late-stage trial. Reuters
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…